Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732957 | 0.89 | NAMPT (0.54) | OPRM1OPRK1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL4091949 | 0.88 | CHEK2 (0.43) | OPRM1OPRK1NAMPTHPGDFGFR1 | |
| SCHEMBL5732760 | 0.86 | FGFR1 (0.52) | OPRM1OPRD1OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL4085613 | 0.86 | CHEK2 (0.48) | OPRM1OPRK1MEN1KMT2AALDH1A1 | |
| SCHEMBL5463332 | 0.86 | ITGB3 (0.47) | OPRM1OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL4092708 | 0.85 | ALDH1A1 (0.44) | OPRM1OPRD1OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL4092958 | 0.82 | FGFR1 (0.42) | OPRM1OPRK1NAMPTFGFR1 | |
| SCHEMBL4082100 | 0.82 | FAAH (0.48) | OPRM1OPRD1OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL4093387 | 0.82 | OPRM1 (0.48) | OPRM1OPRD1OPRK1KDM4EMEN1 | |
| SCHEMBL4088434 | 0.82 | FAAH (0.48) | MEN1KMT2ANPC1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080078-B1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC (US) | 2006-02-01 | — | — | EP | claimed |
| US-6589954-B1 | Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful | SCIOS, INC. | 2003-07-08 | — | — | US | claimed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1707205-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
| WO-2003084539-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084503-A2 | P38 KINASE INHIBITORS FOR TREATING MUCUS HYPERSECRETION_ | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| US-6589954-B1 | Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful | SCIOS, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | disclosed |
| EP-1080078-A1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1999061426-A1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | OPRM1 289/4885OPRD1 385/4885OPRK1 191/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | OPRM1 1291/4885OPRD1 552/4885OPRK1 249/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | OPRM1 1515/4885OPRD1 1741/4885OPRK1 485/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | OPRM1 1291/4885OPRD1 552/4885OPRK1 249/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | OPRM1 1515/4885OPRD1 1741/4885OPRK1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.